Newest
-
Chinese enterprise initiates major irrigation project in Timor-Leste, boosting agriculture and strengthening bilateral bonds
-
Focus on Europe: Carronade Capital Management's Market Expansion Strategy
-
Carronade Capital Management Announces Expansion into Europe, Deepening its Services for Global High Net Worth Clients and Family Offices
-
Deliberation Meeting on Global Forest Environment Standards and Forest Environment Index was held at One Heung Kong, with China’s Solutions Elevated to Global Standards
DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development
2025-02-14
IDOPRESS
SEOUL,South Korea,Feb. 13,2025 -- DAAN Biotherapeutics,a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies,has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the development and commercialization of Antibody-Drug Conjugates (ADC).
By leveraging DAAN Biotherapeutics' next-generation antibody technology,built upon its exceptional target discovery and antibody development capabilities,LigaChem Biosciences is now positioned to take a significant step forward in ADC development for solid tumor patients.
DAAN Biotherapeutics has successfully established a proprietary pipeline for efficiently developing antibodies targeting overexpressed tumor targets in solid cancers through a strategic partnership with OmniAb.
Byoung Chul Cho,MD,the CEO of DAAN Biotherapeutics,stated,"We will continue to develop state-of-the-art antibodies targeting solid tumors and collaborate with global pharmaceutical companies in the ADC field. Beyond ADCs,we also aim to become a global leader in solid tumor-targeting T-cell engagers using our proprietary TACTIC (Tumor Targeting Conditionally Activated T Cell Engager) platform."